colab
we are not here to fit in
.png)
designed for
systems change
the cancer collaborative is a catalyst for change — where disruptive ideas and creative strategy come together to challenge systems, influence policy, and drive real impact for people affected by cancer.
patient centricity: why it matters
patient voice
DISRUPT
the need for collaboration in precision medicine, with TFRI digital health & discovery
precision oncology
#KNOWvember
Adoption of Novel therapeutics in the Canadian
healthcare system: learnings from CAR T cell therapy
disruptive technologies
car t-cell therapy
RHC 2025. The Evolution of Accelerated Access Pathways in Canada
system & sustainability
RHC
looking back to move forward. learning from the implementation of CAR T in canada
disruptive technologies
car t-cell therapy
US cancer moonshot
system & sustainability
crisis to catalyst
patient focused health policy
patient voice
cancer policy
it's time to put patients at the front of the line. rapid access for project orbis could be a start
HTA & value
HTA & value
patient and patient group engagement in cancer clinical trials. a stakeholder charter
patient voice
PACT
canadian cancer clinical trials stakeholder charter
patient voice
PACT
breast cancer & biosimilars
system & sustainability
biosimilars
All.Can initiative improving efficiency in cancer care
system & sustainability
All.Can
access and reimbursement from the industry perspective, with mark oatway (astrazeneca canada)
precision oncology
#KNOWvember
HTA engagement
HTA & value
HTA & value
Let’s put Patients at the front of
the line...Rapid access for Project
Orbis drugs could be a start. CAPT 2022
system & sustainability
access & innovation
CBQA 2024. Precision Oncology in Cnada. Who Pays?
precision oncology
precision oncology & diagnostics
the burden of cancer in canada
system & sustainability
crisis to catalyst
EU beat cancer
system & sustainability
crisis to catalyst
why we need to fix cancer care in canada now
system & sustainability
cancer action now alliance
beat cancer policy paper
system & sustainability
Beat Cancer Coalition
possible avenues to speed up patient access
HTA & value
HTA & value
biosimilar drugs
system & sustainability
biosimilars
towards sustainable cancer care. reducing inefficiencies, improving outcomes. a policy report from the all.ca initiative
system & sustainability
All.Can
the importance of collaboration, with mark oatway (astrazeneca canada)
precision oncology
#KNOWvember
data collection in the age of RWE. HTA engagement. a colab series colabXpulseinfoframe
HTA & value
HTA & value
CDDF 2021. The Role of Patients in Drug Development and Innovation. From Patient Involvement to Patient Partnerships
system & sustainability
patient centricity
economics of cancer
system & sustainability
crisis to catalyst
US cancer moonshot
system & sustainability
crisis to catalyst
gene therapy: international regulatory and health technology assessment (HTA) activities and reimbursement status
disruptive technologies
car t-cell therapy
improving access to innovative cancer therapies in canada
HTA & value
HTA & value
adoption of novel therapeutics in the canadian healthcare system. learnings from CAR T t cell therapy
HTA & value
car t-cell therapy
international policies on the appropriate use of biosimilar drugs
system & sustainability
biosimilars
CADTH review process for cell and gene therapies
disruptive technologies
car t-cell therapy